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Abstract
The Pastorex
H (BioRad) rapid agglutination test is one of the main rapid diagnostic tests (RDTs) for meningococcal disease
currently in use in the ‘‘meningitis belt’’. Earlier evaluations, performed after heating and centrifugation of cerebrospinal
fluid (CSF) samples, under good laboratory conditions, showed high sensitivity and specificity. However, during an
epidemic, the test may be used without prior sample preparation. Recently a new, easy-to-use dipstick RDT for
meningococcal disease detection on CSF was developed by the Centre de Recherche Me ´dicale et Sanitaire in Niger and the
Pasteur Institute in France. We estimate diagnostic accuracy in the field during the 2006 outbreak of Neisseria meningitidis
serogroup A in Maradi, Niger, for the dipstick RDT and Pastorex
H on unprepared CSF, (a) by comparing each test’s sensitivity
and specificity with previously reported values; and (b) by comparing results for each test on paired samples, using
McNemar’s test. We also (c) estimate diagnostic accuracy of the dipstick RDT on diluted whole blood. We tested unprepared
CSF and diluted whole blood from 126 patients with suspected meningococcal disease presenting at four health posts. (a)
Pastorex
H sensitivity (69%; 95%CI 57–79) was significantly lower than found previously for prepared CSF samples [87% (81–
91); or 88% (85–91)], as was specificity [81% (95%CI 68–91) vs 93% (90–95); or 93% (87–96)]. Sensitivity of the dipstick RDT
[89% (95%CI 80–95)] was similar to previously reported values for ideal laboratory conditions [89% (84–93) and 94% (90–
96)]. Specificity, at 62% (95%CI 48–75), was significantly lower than found previously [94% (92–96) and 97% (94–99)]. (b)
McNemar’s test for the dipstick RDT vs Pastorex
H was statistically significant (p,0.001). (c) The dipstick RDT did not perform
satisfactorily on diluted whole blood (sensitivity 73%; specificity 57%). Sensitivity and specificity of Pastorex
H without prior
CSF preparation were poorer than previously reported results from prepared samples; therefore we caution against using
this test during an epidemic if sample preparation is not possible. For the dipstick RDT, sensitivity was similar to, while
specificity was not as high as previously reported during a more stable context. Further studies are needed to evaluate its
field performance, especially for different populations and other serogroups.
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Introduction
Every year during the meningitis season (approximately January–
May), countries in the African meningitis belt are at risk from
outbreaksofmeningococcalmeningitis.Inordertoeffectivelylaunch
a mass vaccination campaign once an outbreak has been declared,
the correct strain responsible for the outbreak must be identified.
Traditional laboratory diagnostic methods for strain identification
(such as culture and PCR) are expensive and can be complicated in
terms of equipment and training needed. Often only a national or
reference laboratory has the capacity to carry out these types of tests,
as laboratory facilities in remote areas hit by an outbreak may be
limited or non-existent.[1] Thus, samples are often transferred to the
better-equipped central laboratories, which can be some distance
away. The time taken for sample transfer, as well as the hot, dusty
conditions experienced during the meningitis season, can lead to
high levels of sample contamination, with inconclusive results.
Pastorex
H rapid agglutination test
Since 2002, the World Health Organization has recommended
pre-positioning rapid agglutination tests in peripheral laboratories
prior to the meningitis season in countries in the African
meningitis belt. One such test is the Pastorex
H rapid agglutination
test (Bio-Rad Laboratores, Inc., Marne-la-Coquette, France),
which can detect Neisseria meningitidis (N. meningitidis) serogroups
A, C and Y/W135, as well as N. meningitidis serogroup B/E.coli,
Haemophilus influenzae, Streptococcus pneumoniae and Group B
Streptococcus. It is the main rapid agglutination test currently in
use in the field for identification of N. meningitidis serogroup
W135,[2] although it cannot distinguish N. meningitidis serogroup
W135 from serogroup Y. The Pastorex
H test also carries certain
constraints. Test reagents must be kept under cold chain (between
+4uC and +8uC), and the manufacturer recommends heating and
centrifuging cerebrospinal fluid (CSF) samples prior to using the
test. The test kit contains reagents for 25 tests: once opened, all
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practical for pre-positioning in peripheral health posts, but may be
better used at district or regional hospital laboratory level. In
epidemic situations at peripheral level, in the absence of
equipment (centrifuge and/or heating device) or lack of trained
laboratory personnel, there is sometimes little option other than to
use the Pastorex
H test on unprepared CSF, i.e. without prior
heating or centrifugation (Me ´decins sans Frontie `res (MSF) internal
communication).
Several studies have investigated the performance of the
Pastorex
H test under ideal laboratory conditions. Estimated
sensitivity and specificity were 84% (95%CI 60–97) and 89%
(76–96), respectively, for N. meningitidis serogroup W135,[2] while
for serogroup A these were estimated at 88% (95%CI 85–91) and
93% (87–96), respectively.[3,4] Some difficulties in reading the test
results have been reported anecdotally by Pastorex
H test users
(MSF internal communication), though mainly during outbreaks
of serogroup W135. These could be due to user variation (e.g.
differing interpretation of weak or borderline agglutination), or
practical difficulties such as less than ideal kit conservation
conditions in the field. In addition, the high ambient temperature
and extremely dry conditions during meningitis season can lead to
the drops of CSF and/or reagent drying out on the test strip before
the results can be read. There may also be user error, such as the
failure to follow the manufacturer-recommended sample prepa-
ration procedures of heating and centrifugation of the sample,
mentioned above. To our knowledge, to date, investigation of the
performance of this agglutination test under field conditions
during an outbreak (i.e. using unprepared CSF) has not yet been
conducted.[5]
The first aim of this study was therefore to observe whether the
Pastorex
H test, when conducted under ‘field’ conditions (with no
prior sample preparation) had similar sensitivity and specificity to
thistestwhenconductedfollowingmanufacturers’recommendations
(i.e. with prior sample preparation; as reported previously[3,4]).
The dipstick rapid diagnostic test (RDT)
Recently, the Pasteur Institute in Paris and the Centre de
Recherche Me ´dicale et Sanitaire (CERMES) in Niamey, Niger
developed a new dipstick RDT for the diagnosis of N. meningitidis
serogroups A, W135, C and Y without prior sample preparation.
This test exists as a duplex of two dipsticks (RDT1 and RDT2) in
which RDT1 detects N. meningitidis serogroups A and W135/Y,
while RDT2 detects N. meningitidis serogroups C and Y. An
algorithm based on the results of the two dipsticks thus allows the
detection of N. meningitidis serogroups A, C, W135 or Y. Under
ideal laboratory conditions, the sensitivity and specificity for all
serogroups were 100% when tested on reference strain cultures.
Using frozen CSF samples, sensitivity was 94% for serogroup A,
while specificity was 97%.[5] Results from 847 CSF samples
received from suspected meningitis patients at CERMES in Niger
from January 2005 to September 2006 showed that the dipstick
RDT had a sensitivity of 89% (95%CI 84–93) and a specificity of
94% (95%CI 92–96).[1]
Our second aim was therefore to investigate whether this
dipstick RDT, when conducted under ‘real’ field conditions, had a
similar sensitivity and specificity to what has been previously
reported for this new test under ‘ideal’ conditions. In addition, as
the dipstick RDT, when commercialized, would have its main
application at the peripheral health centre level, we wanted to
directly compare results when the test was conducted on the same
samples by (a) trained laboratory technicians in the laboratory vs
(b) health post nurses in the field.
Finally, the fourth aim was to compare diagnostic accuracy of
the dipstick RDT performed in the field on unprepared CSF with
the Pastorex
H test performed under the same conditions.
As well as measuring performance of the dipstick RDT on CSF,
we conducted a small sub-study to investigate how well this RDT
performed on diluted whole blood samples.
Here we report on these evaluations of the Pastorex
H rapid
agglutination test and the dipstick RDT, conducted in the field on
unprepared CSF samples, as well as on diluted whole blood,
during an epidemic in Niger in March-April 2006, using culture
and/or PCR as the reference standard.
Materials and Methods
Study design, site and population
In previous evaluations, sensitivity and specificity of the
Pastorex test for N. meningitidis serogroup A were found to be
88% and 93%, respectively, when the test was conducted following
manufacturers’ instructions for heat and centrifugation of sample
prior to testing.[3,4] We hypothesised that values for both
sensitivity and specificity would be lower if the sample was not
adequately prepared. We therefore calculated a sample size of 200,
based on a prevalence of 70% among suspect cases presenting at
health clinics, with targeted values for sensitivity and specificity of
at least 70% (68%) and 80% (610%), respectively.
Patients were recruited prospectively between 27 February and
18 March 2006 in Niger during the outbreak of N. meningitidis
serogroup A, which occurred in the Health District of Madarounfa
in the Region of Maradi. The study setting was four peripheral
health posts (Danissa, N’Yelwa, Safo and Serkin Yama), selected
based on the following criteria: (a) having a high enough number
of suspect cases during 1–2 weeks prior to the start of the study; (b)
presence of health staff working at the health post who were
trained in the lumbar puncture procedure and who could be
trained to use the dipstick RDT; (c) availability of laboratory
technicians to conduct the Pastorex
H tests on-site; (d) presence of a
functioning refrigerator and freezer for stocking the Pastorex
H test
reagents and freezing the CSF samples for transport, respectively.
Both the National Ethical Review Committee of Niger and the
Comite ´ de Protection des Personnes (CPP ‘‘Ile de France XI’’,
France) approved the study prior to starting inclusions.
A suspect case was defined as a patient with clinical signs and
symptoms of bacterial meningitis (see Appendix S1) presenting at
one of the four health posts in the study. All suspect cases over the
age of 2 months, and for whom an informed consent form had
been signed, were eligible for inclusion. This form was read in the
local language to the patient (or, for those who were under 15
years of age or in an altered state of consciousness, to the parent or
other person accompanying the patient) by the attending health
personnel at the health post. In each health post, a lumbar
puncture was performed by a clinical officer in order to obtain a
CSF sample, and blood samples were obtained by a finger-prick.
Laboratory procedures
Approximately 4 ml of CSF was obtained from each eligible
suspect case. A medical doctor from the research team supervised
the lumbar puncture procedure in each health post at the start of
the study and provided support and/or re-training as appropriate.
Participating health posts were provided with Pastorex
H kits and
dipstick RDT kits supplied by CERMES in Niamey (produced by
the Institut Pasteur in Madagascar in December 2005). Bottles of
trans-isolate (TI) media, for transport of the CSF for culture, were
provided by the Norwegian Institute of Public Health (NIPH) in
Oslo, and by CERMES.
Meningitis RDT Evaluation
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about 1 ml, which was immediately frozen for transport to
CERMES for PCR. The health post nurse then inoculated the TI
bottle with about 1 ml CSF from the second tube. Then 400 mlo f
CSF was removed from this tube and divided between two smaller
tubes for immediate testing with the two dipstick RDTs by the
health post nurse. The tube was later collected by the laboratory
technician, for performing the Pastorex
H test on the remaining
CSF. Where possible, the Pastorex
H tests were conducted in a
separate room from the dipstick RDTs, often in batches.
If insufficient CSF was collected for all tests, the priority was to
inoculate the CSF into TI for culture, or freeze the sample for
PCR, or both.
Weekly during the study, frozen CSF samples and bottles of TI
were transported to CERMES in Niamey, where both culture and
PCR were performed, as well as a repeat of the dipstick RDTs.
Briefly, after inoculating CSF at 36uC in chocolate blood medium
and polyvitex, for 16–24 h, isolated colonies were re-inoculated on
Muller Hinton media for a further 16–24 h. Colonies were then
Gram stained and tested using API
H NH (Biome ´rieux). On the
third day, isolates were serogrouped using rabbit anti-sera (BD
Difco
TM) and tested for antibiotic resistance. PCR was performed
using previously described methods.[4–8]
Different technicians performed culture and PCR, without
knowledge of each other’s results, and one technician (author SC)
performed all the repeat dipstick RDTs in one batch at the end of
the study. Results from all three tests were collated by CERMES
and sent to Epicentre for analysis.
In addition to tests performed on CSF, 2 drops of blood
(approximately 20 ml) were taken by the laboratory technician
from a finger of each suspect case-patient and diluted with 180 ml
phosphate-buffered saline in a small tube. A dipstick RDT was
then conducted on these diluted whole blood samples in the field.
At the end of the study, a random 20% of CSF tubes was sent to
the NIPH in Oslo for quality control by PorA gene-based nested
PCR[9] followed by capsule gene-specific PCR on CSF positive
with the PorA gene PCR.[10] In addition, 10 of the N. meningitidis
serogroup A positive cultures were sent to the NIPH for PCR
strain typing by MLST, PorA and FetA genotyping.
Treatment, free of charge, following the treatment protocol for
epidemic meningococcal meningitis, was provided by MSF to all
suspected patients at participating health posts. Treatment was
based on clinical features, not on results of the rapid tests under
evaluation.
Analysis
Sensitivity and specificity. Data were entered onto EpiData
H
Version 3.1 (EpiData, Odense, Denmark) and analysed initially using
Stata
TM Version 8.2 (StataCorp, College Station, TX, USA). The
sensitivity and specificity were calculated, with 95% confidence
intervals (95%CI). A reference standard of culture and/or PCR was
selected as it had been used in previous evaluations of thesetests,[2–5]
and it was defined in the following way: positive samples were those
having a positive result for either culture or PCR. Negative samples
were those which were negative for both, or negative for one and not
done or uninterpretable for the other. Samples which were
contaminated in culture, and those with inhibited PCR results,
were defined as uninterpretable for culture and PCR, respectively.
Samples missing a result for any one of the tests under evaluation
were excluded, so that we could directly compare sensitivity and
specificity estimations across the different tests.
Comparative analyses
Aims 1 and 2: Comparison of independent proportions.
The sensitivity and specificity calculated for the Pastorex
H test were
Figure 1. Schematic of all rapid and confirmatory diagnostic tests conducted on cerebrospinal fluid (CSF) and blood samples, with
results obtained for each test. Shaded section shows confirmatory tests (‘reference standard’).
doi:10.1371/journal.pone.0007326.g001
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prepared CSF samples (Aim 1), and those for the dipstick RDT
conducted in the field were compared with published results for
this test conducted under ideal laboratory conditions (Aim 2). The
t-test was used to compare proportions, with p-values,0.05
considered as statistically significant. In addition, the 95% CIs of
the differences between these independent proportions were
estimated, using Stata
TM Version 10.0 (StataCorp, College
Station, TX, USA), Newcombe’s method.[11]
Aims 3 and 4: Comparison of paired samples. McNemar’s
test takes into account paired samples, which occurs when each
sample has had more than one diagnostic test, as was the case in our
study. This permitted us to compare results from the following pairs
of samples: (a) dipstick RDT performed on CSF in the field vs the
laboratory (Aim 3); (b) dipstick RDT vs Pastorex
H test, both
performed on CSF in the field (Aim 4). Analysis (a) allowed us to
examine whether the dipstick RDT performance varied by the
conditions under which the test was performed, or by who
performed it, while analysis (b) allowed us to compare the
difference between two different tests when both were performed
under similar conditions in the field.
Results
There were 146 suspect case-patients for whom lumbar
punctures were conducted at the 4 health posts during this study.
As three of these procedures failed to produce CSF, blood sampling
was only attempted for the remaining 143 case-patients. Four died
before blood could be collected and, for two others, the laboratory
technician was not available for blood collection prior to starting
treatment. Thus blood samples were collected from a total of 137
(94%) patients with suspected meningococcal disease (Figure 1).
Of the 143 CSF samples, 82 (57%) were positive by the reference
standard ofcultureand/orPCR.Flow diagrams of the performance
of the dipstick RDT and the Pastorex
H test, both conducted in the
fieldonunpreparedCSF,areshowninFigures2and3,respectively.
(Additional flow diagrams for performance of the dipstick RDT on
unprepared CSFin the laboratory,and on undiluted whole blood in
the field, are shown in Appendices S2 and S3, respectively.)
Sensitivity and specificity
After exclusions due to insufficient CSF (n=8) or no blood
being collected (n=6), or because of uninterpretable test results
Figure 2. Flow diagram showing performance of the dipstick rapid diagnostic test (RDT) conducted in the field on unprepared
cerebrospinal fluid, against a reference standard of culture and/or PCR, to diagnose N. meningitidis serogroup A (NmA). (Note: ‘‘No
reference standard’’ indicates those samples for which the reference standard result was undetermined or where there was not enough CSF
remaining to conduct PCR).
doi:10.1371/journal.pone.0007326.g002
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CSF and blood tests (88%) (Table 1). Culture had the greatest
proportion of uninterpretable results (19/142; 13%) compared
with all other rapid and confirmatory tests conducted (#2%).
There were 73 samples confirmed positive by the reference
standard out of the 126 samples having all test results; giving a
Figure 3. Flow diagram showing performance of the Pastorex
H test conducted in the field on unprepared cerebrospinal fluid,
against a reference standard of culture and/or PCR, to diagnose N. meningitidis serogroup A (NmA). (Note: ‘‘No reference standard’’
indicates those samples for which the reference standard result was undetermined or where there was not enough CSF remaining to conduct PCR).
doi:10.1371/journal.pone.0007326.g003
Table 1. Comparison of results for each of the tests conducted vs the reference standard,* for the 126 samples having clear (either
positive or negative) results for all tests.
Reference standard* Reference standard*
Test site (fluid; test type
{) + 2 TOTAL
(1) Health post + 65 20 85
(CSF; dipstick RDT) 2 83 3 4 1
(2) Laboratory + 64 17 81
(CSF; dipstick RDT) 2 93 6 4 5
(3) Health post + 53 23 76
(Blood; dipstick RDT) 2 20 30 50
(4) Health post + 50 10 60
(CSF; Pastorex
H) 2 23 43 66
TOTAL 73 53 126
*Reference standard: culture and/or PCR.
{RDT: rapid diagnostic test.
doi:10.1371/journal.pone.0007326.t001
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49–67).
An overview of the performance of each of the tests under
evaluation in our study is provided in Table 2.
Aims 1 and 2
The sensitivity and specificity of the Pastorex
H test on
unprepared CSF samples were both lower than found previously
using prepared CSF samples (Aim 1; Table 3). For sensitivity this
difference was statistically significant using both comparative
statistical tests: p,0.05 for the sensitivity in the current study
compared with each of the prior studies;[3,4] difference between
the sensitivity in the current study and that found by Borel
et al.[3]=0.19 (95%CI 0.08–0.31); difference between the
sensitivity in the current study and that found by Djibo
et al.[4]=0.18 (95%CI 0.07–0.30). Similarly, the specificity for
the PastorexH test was significantly lower (p,0.05) than in the
prior studies, with a difference of 0.12 (95%CI 0.02–0.25)
(Table 3).
The sensitivity of the dipstick RDT under field conditions was
similar to what has been previously reported when this test was
performed on CSF under ideal laboratory conditions (Aim 2;
Table 3). In our study, RDT sensitivity was 89% (95%CI 80–95)
vs earlier reports of 89% (95%CI 84–93),[1] (p=0.99); and 94%
(95%CI 90–96),[5] (p=0.13). The specificity in our study,
however, was significantly lower than found previously
(p,0.05).[1,5] The differences between the specificity in the
current study and those reported previously [1,5] were 0.32
(95%CI 0.20–0.46) [1] and 0.35 (95%CI 0.23–0.48) [5].
Aims 3 and 4
Table 4 shows a comparison of the results from the dipstick
RDT performed on unprepared CSF in the field vs the same test
performed in the laboratory. McNemar’s test on these 137 paired
sample results gave x
2=0.35 (p=0.35), i.e. the dipstick RDT,
when performed on the same samples under different conditions
by different technicians does not give statistically significantly
different results (Aim 3). However, the McNemar’s test on paired
results from the dipstick RDT vs the Pastorex
H test, both
performed on unprepared CSF in the field (Table 5), gave a
x
2=24.5 (p=0.000001), which is statistically significant (Aim 4).
The latter overall result indicates that the dipstick RDT is more
likely than the Pastorex
H test to give a positive result, although it
does not tell us which of these tests is more likely to give the correct
result. For this, first we divided sample results into those which
were positive, and those negative, by the reference standard. Then
Table 2. Sensitivity and specificity, with 95% confidence intervals (95%CI) for cerebrospinal fluid (CSF) and blood samples from
126 suspect case-patients during the Neisseria meningitidis serogroup A outbreak in Niger; February–March 2006.*
Type (site) of RDT
{ Sample type Sensitivity % (95%CI) Specificity % (95%CI)
RDT (field) CSF 89 (80–95) 62 (48–75)
RDT (laboratory) CSF 88 (78–94) 68 (54–81)
RDT (field) Blood 73 (61–82) 57 (42–70)
Pastorex
H (field) CSF 69 (57–79) 81 (68–91)
*Sensitivity and specificity were calculated versus a ‘reference standard’ of culture and/or PCR.
{RDT: dipstick rapid diagnostic test.
doi:10.1371/journal.pone.0007326.t002
Table 3. Results of statistical comparison tests conducted between the sensitivity and specificity of diagnostic tests performed in
the field on unprepared CSF during an epidemic in Niger, February–March 2006, vs sensitivity and specificity results from the same
diagnostic tests conducted in earlier studies, using prepared CSF.*
Diagnostic test Study Sensitivity % (95%CI)
Statistical comparisons:
{
(1) p-value; (2) difference
(95%CI) Specificity % (95%CI)
Statistical comparisons:
(1) p-value; (2) difference
(95%CI)
PastorexH Current study 69 57–79 81 68–91
Prior study: Ref 3 88 85–91 (1) 0.00005 93 90–95 (1) 0.02
(2) 0.19 (0.08–0.31) (2) 0.12 (0.02–0.25)
Prior study: Ref 4 87 81–91 (1) 0.00045 93 87–96 (1) 0.01
(2) 0.18 (0.07–0.30) (2) 0.12 (0.02–0.25)
RDT
{ Current study 89 80–95 62 48–75
Prior study: Ref 1 89 84–93 (1) 0.99 94 92–96 (1) ,0.00001
(2) 0.00 (20.08–0.10) (2) 0.32 (0.20–0.46)
Prior study: Ref 5 94 96–96 (1) 0.13 97 94–99 (1) ,0.00001
(2) 0.05 (20.01–0.15) (2) 0.35 (0.23–0.48)
*Results from the current study are shown in bold type; statistically significant results are shown in italic type.
{(1) P-value for a comparison between the two proportions; (2) the difference between two independent proportions, with 95%CI, calculated using Newcombe’s
method (see text).
{RDT: dipstick rapid diagnostic test.
doi:10.1371/journal.pone.0007326.t003
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samples separately (Tables 6 and 7, respectively). Comparing the
dipstick RDT to the Pastorex
H test for all positive samples gave
x
2=14.2 (p=0.0002), thus the dipstick RDT is more likely than
the Pastorex
H test to correctly diagnose a positive sample as
positive, and this is statistically significant. For all negative samples,
x
2=10.3 (p=0.0013); thus the dipstick RDT is more likely than
the Pastorex
H test to incorrectly diagnose a negative sample as
positive, and this difference is also statistically significant.
Thirty CSF samples were sent to the NIPH in Oslo for quality
control. Of these, 19 (63%) were positive by PCR for N. meningitidis
serogroup A, of which 18 (95%) had the same PorA sub-type
(P1.20,9). When compared with PCR results from CERMES in
Niger, the overall concordance between the two laboratories for
these 30 samples was 83% (95%CI 65–94). The percentage
agreement for PCR conducted at CERMES for those samples
determined as ‘true positive’ by the NIPH was 87% (95%CI
75–98); while for those considered as ‘true negatives’, the
agreement was 78% (95%CI 60–97). A representativity test for
the 30 samples used in the quality control analysis revealed that
these were representative of the samples collected in the field.
Discussion
We show that the sensitivity and specificity of the Pastorex
H test
and specificity of the dipstick RDT, performed on unprepared
samples (i.e. without prior heating and centrifugation), in the field
under epidemic conditions, are statistically significantly lower than
previously reported values performed on prepared sam-
ples.[1,3,4,5] We also found that the dipstick RDT performed at
a central laboratory did not give significantly different results for
sensitivity and specificity compared with testing under field
conditions (Table 2). Finally, we show that the dipstick RDT,
performed on the same samples, had higher sensitivity but lower
specificity than the Pastorex
H test, and that these differences were
statistically significant. Thus, under these conditions, the dipstick
RDT is better at correctly ruling out disease (as it has a lower false
negative rate), while the Pastorex
H test is better at confirming
disease (having a lower false positive rate). The performance of the
dipstick RDT on diluted whole blood samples was not satisfactory,
as specificity was very low (57%). The sensitivity of this test on
diluted whole blood, however, was similar to that of the Pastorex
H
test conducted on unprepared CSF (73% vs 69%).
There were several limitations to our study. First of all, there
were not enough ‘true negatives’ for us to be able to calculate
acceptably accurate estimates of specificity for either of the rapid
tests. Secondly, we only performed the Pastorex
H test on
unprepared samples, so we can make no direct comparison with
the test performed on prepared samples. Our results for the
Pastorex
H test therefore have to be compared with those from
previous studies, which is not ideal. In addition, our study had a
smaller sample size than expected (146 vs 200), which occurred
because, by the time we began the study, measures were already in
place to bring the outbreak under control, and fewer patients with
suspected meningococcal disease were presenting to health posts
with symptoms. In particular, the sample size for patients with
suspected meningococcal disease who were negative for N.
meningitidis serogroup A was smaller than expected. These factors
resulted in wide confidence limits (less precision) for both
sensitivity and specificity. Finally, the PCR methods used in the
laboratory in Niger (CERMES) and that in Oslo (NIPH) were
based on different gene targets. In addition, the NIPH method
involved a nested PCR, which appears to have somewhat greater
Table 5. Comparison of results obtained from different tests
used for diagnosis of Neisseria meningitidis serogroup A from
unprepared CSF during an epidemic in Niger, February–March
2006: dipstick rapid diagnostic test (RDT) vs Pastorex
H.
RDT RDT
+ 2 Total
Pastorex
H + 60 2 62
2 30 42 72
Total 90 44 134
doi:10.1371/journal.pone.0007326.t005
Table 6. Comparison of results from the Pastorex
H test vs the
dipstick rapid diagnostic test (RDT) performed in the field on
unprepared CSF during an epidemic in Niger, February–March
2006, for all positive samples by the reference standard of
culture and/or PCR (N=76).
RDT RDT
+ 2 Total
Pastorex
H + 51 1 52
2 17 7 24
Total 68 8 76
doi:10.1371/journal.pone.0007326.t006
Table 4. Comparison of results obtained using the dipstick
rapid diagnostic test (RDT) for diagnosis of Neisseria
meningitidis serogroup A from unprepared CSF during an
epidemic in Niger, February–March 2006: tests conducted in
the laboratory vs on-site at the health post.
RDT
(laboratory)
RDT
(laboratory)
+ 2 Total
RDT + 74 17 91
(health post) 2 12 34 46
Total 86 51 137
doi:10.1371/journal.pone.0007326.t004
Table 7. Comparison of results from the Pastorex
H test vs the
dipstick rapid diagnostic test (RDT) performed in the field on
unprepared CSF during an epidemic in Niger, February–March
2006, for all negative samples by the reference standard of
culture and/or PCR (N=58).
RDT RDT
+ 2 Total
Pastorex
H + 91 1 0
2 13 35 48
Total 22 36 58
doi:10.1371/journal.pone.0007326.t007
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the Niamey and Oslo PCR results in the quality control testing of a
subset of samples.
Further estimates should be made using the dipstick RDTs in
similar conditions, but with a larger sample size, in order to
provide more precise estimates. It would also be useful to test the
dipstick RDT performance on other populations and for other
serogroups to assess the test’s viability for widespread use
throughout the meningitis belt. Clearly, to clarify the relative
advantages and disadvantages of the Pastorex
H and dipstick RDT
tests, further direct comparative studies must be conducted.
Even though the performance of the dipstick RDT on diluted
whole blood was not as good as that on unprepared CSF, the test
shows some promise, especially in terms of its sensitivity and ease
of use. In particular, further development of this test is warranted if
we are one day to avoid the difficult, often painful and potentially
harmful lumbar puncture procedure. Even if the dipstick RDT, for
either CSF or whole blood, never proves sufficiently accurate
enough for bedside use (i.e. for physicians to make a decision on
individual treatment), further development of this test should mean
that the sub-Saharan African region could have a faster, cheaper
and easier alternative for determination of a meningococcal
meningitis outbreak. We strongly urge others to evaluate this test
when investigating future outbreaks so that those involved in its
development can have as much information as possible in order to
further fine-tune this much-needed test.
Finally, because of logistical constraints during an epidemic, the
Pastorex
H test is sometimes used without prior sample preparation.
Based on our findings, i.e. low sensitivity and specificity, we
recommend that this test should not be used during epidemics
unless prior centrifugation and heating of CSF can be guaranteed.
The use of hand-held centrifuges and battery-operated water-
heaters should be explored in field settings to investigate whether,
during epidemic conditions, they could serve as reliable alterna-
tives to be used for CSF sample preparation prior to the Pastorex
H
test.
Supporting Information
Appendix S1
Found at: doi:10.1371/journal.pone.0007326.s001 (0.03 MB
DOC)
Appendix S2 Flow diagram showing performance of the dipstick
rapid diagnostic test (RDT) against a reference standard of culture
and/or PCR, to diagnose N. meningitidis serogroup A (NmA)
conducted in the laboratory on unprepared cerebrospinal fluid.
(Note: ‘‘No reference standard’’ indicates those samples for which
no reference standard result was obtained).
Found at: doi:10.1371/journal.pone.0007326.s002 (0.33 MB
DOC)
Appendix S3 Flow diagram showing performance of the dipstick
rapid diagnostic test (RDT) against a reference standard of culture
and/or PCR, to diagnose N. meningitidis serogroup A (NmA)
conducted in the field on undiluted whole blood. (Note: ‘‘No
reference standard’’ indicates those samples for which no reference
standard result was obtained).
Found at: doi:10.1371/journal.pone.0007326.s003 (0.35 MB
DOC)
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